164 related articles for article (PubMed ID: 25857058)
1. [Erlotinib, sunitinib, and everolimus].
Takahashi M
Nihon Rinsho; 2015 Mar; 73 Suppl 3():409-13. PubMed ID: 25857058
[No Abstract] [Full Text] [Related]
2. Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors.
Liakakos T; Roukos DH
Future Oncol; 2011 Sep; 7(9):1025-9. PubMed ID: 21919689
[No Abstract] [Full Text] [Related]
3. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
Crippa S; Partelli S; Boninsegna L; Falconi M
Ann Oncol; 2012 Jul; 23(7):1928. PubMed ID: 22753260
[No Abstract] [Full Text] [Related]
4. A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors.
Capdevila J; Tabernero J
Cancer Discov; 2011 Aug; 1(3):213-21. PubMed ID: 22586573
[TBL] [Abstract][Full Text] [Related]
5. Advances in pancreatic neuroendocrine tumor treatment.
van der Veldt AA; Kleijn SA
N Engl J Med; 2011 May; 364(19):1873; author reply 1873-5. PubMed ID: 21561355
[No Abstract] [Full Text] [Related]
6. Promising advances in the treatment of malignant pancreatic endocrine tumors.
Jensen RT; Delle Fave G
N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
[No Abstract] [Full Text] [Related]
7. New treatments of pancreatic neuroendocrine tumors: why using them? How to use them?
Raymond E; Ruszniewski P
Target Oncol; 2012 Jun; 7(2):91-2. PubMed ID: 22669625
[No Abstract] [Full Text] [Related]
8. New target therapies for patients with neuroendocrine tumors of the pancreas.
Baltogiannis G; Katsios C; Roukos DH
Expert Rev Gastroenterol Hepatol; 2011 Oct; 5(5):563-6. PubMed ID: 21910571
[No Abstract] [Full Text] [Related]
9. Oral agents for treatment of patients with advanced pancreatic neuroendocrine tumors: could pharmaeconomic, cost-effectiveness data play a significant role?
Barna ME; Uomo I; Pastorello M
JOP; 2013 Jan; 14(1):102-4. PubMed ID: 23306347
[No Abstract] [Full Text] [Related]
10. Sunitinib and everolimus in pancreatic neuroendocrine tumors.
Procopio G; Pusceddu S; Buzzoni R
Tumori; 2012; 98(3):394. PubMed ID: 22825518
[No Abstract] [Full Text] [Related]
11. [Adverse effects of new oncologic therapies].
Weisshaupt Ch; Budak K; Pestalozzi B
Praxis (Bern 1994); 2011 Jul; 100(15):885-91; quiz 890. PubMed ID: 21792802
[No Abstract] [Full Text] [Related]
12. Translational medicine: Cancer lessons from mice to humans.
Tuveson D; Hanahan D
Nature; 2011 Mar; 471(7338):316-7. PubMed ID: 21412332
[No Abstract] [Full Text] [Related]
13. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
14. Novel agents in gastroenteropancreatic neuroendocrine tumors.
Stevenson R; Libutti SK; Saif MW
JOP; 2013 Mar; 14(2):152-4. PubMed ID: 23474560
[TBL] [Abstract][Full Text] [Related]
15. Three new drugs available to fight kidney cancer.
Bankhead C
J Natl Cancer Inst; 2006 Sep; 98(17):1181-2. PubMed ID: 16954469
[No Abstract] [Full Text] [Related]
16. Advances in the treatment of pancreatic neuroendocrine tumours.
Gao F; Visvardis EE; Sita-Lumsden A; Waxman J
QJM; 2012 Sep; 105(9):819-22. PubMed ID: 22383691
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib-associated thrombotic microangiopathy: a significant risk.
Buckley FD; Preston G; Meiklejohn DJ; Adamson D
Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):515. PubMed ID: 24746506
[No Abstract] [Full Text] [Related]
18. [Targeted therapies, prognostic and predictive factors in endocrine oncology].
Hescot S; Baudin E; Borson-Chazot F; Lombès M
Ann Endocrinol (Paris); 2013 Oct; 74 Suppl 1():S13-22. PubMed ID: 24356287
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
[TBL] [Abstract][Full Text] [Related]
20. Recent studies show promise for treating rare pancreatic tumors.
Peres J
J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
[No Abstract] [Full Text] [Related]
[Next] [New Search]
